| Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States |
12 |
| Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation |
12 |
| Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis |
12 |
| Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients |
11 |
| Systematic Review: Targeting HER2 in Bladder Cancer |
9 |
| Early Complications and Mortality following Radical Cystectomy: Associations with Malnutrition and Obesity |
7 |
| Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis |
7 |
| Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review |
6 |
| Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer |
6 |
| Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer |
6 |
| Recovering from Cystectomy: Patient Perspectives |
5 |
| Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies |
5 |
| Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines |
5 |
| Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome |
5 |
| Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the Treatment of Non-Muscle Invasive Bladder Cancer |
4 |
| Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy |
4 |
| Bladder Cancer Genetic Susceptibility. A Systematic Review |
4 |
| The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer |
4 |
| Antibody-Drug Conjugates in Bladder Cancer |
4 |
| Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer |
4 |
| Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7 |
4 |
| Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer |
4 |
| Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer |
4 |
| Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer |
4 |
| Increased Surgical Complications in Smokers Undergoing Radical Cystectomy |
4 |
| Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study |
3 |
| Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract |
3 |
| Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers |
3 |
| Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays |
3 |
| Fatty Acid Patterns Detected By Ambient Ionization Mass Spectrometry in Canine Invasive Urothelial Carcinoma From Dogs of Different Breeds |
3 |
| Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study |
3 |
| Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants |
3 |
| Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC) |
3 |
| Investigating the STING Pathway to Explain Mechanisms of BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications |
3 |
| PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis |
2 |
| Impact of Facility Radiation Patient Volume on Overall Survival in Patients with Muscle Invasive Bladder Cancer Undergoing Trimodality Bladder Preservation Therapy |
2 |
| The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum |
2 |
| Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model |
2 |
| The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study |
2 |
| Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients |
2 |
| Evaluation of Hematuria in a Large Public Health Care System |
2 |
| Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers |
2 |
| Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer |
2 |
| Venous Thromboembolism and Pefi-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study |
1 |
| Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations |
1 |
| Modeling Tumor Heterogeneity in Bladder Cancer: The Current State of the Field and Future Needs |
1 |
| Assessment of a European Bladder Cancer Predictive Model for Non-Muscle Invasive Bladder Cancer in an Australian Cohort |
1 |
| Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention |
1 |
| Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E Qapzola (TM)) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer |
1 |
| Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer |
1 |
